 Sharmilan Thanendrarajan
Concepts (218)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 57 | 2025 | 3013 | 3.930 |
Why?
| | Antibodies, Bispecific | 7 | 2025 | 104 | 1.310 |
Why?
| | Leukemia, Plasma Cell | 2 | 2020 | 33 | 0.810 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2024 | 600 | 0.780 |
Why?
| | Immunotherapy, Adoptive | 5 | 2024 | 156 | 0.670 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 5 | 2025 | 123 | 0.650 |
Why?
| | B-Cell Maturation Antigen | 7 | 2025 | 95 | 0.650 |
Why?
| | Plasma Cells | 6 | 2025 | 233 | 0.630 |
Why?
| | Neoplasms, Plasma Cell | 3 | 2024 | 35 | 0.600 |
Why?
| | Humans | 65 | 2025 | 52459 | 0.550 |
Why?
| | Chromosome Deletion | 2 | 2023 | 138 | 0.550 |
Why?
| | Bone Marrow | 9 | 2022 | 354 | 0.530 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 35 | 0.520 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 461 | 0.490 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 224 | 0.460 |
Why?
| | Proteasome Inhibitors | 1 | 2016 | 101 | 0.450 |
Why?
| | Transplantation, Autologous | 8 | 2024 | 479 | 0.450 |
Why?
| | Immunologic Factors | 1 | 2016 | 114 | 0.450 |
Why?
| | Aged | 23 | 2025 | 10243 | 0.450 |
Why?
| | Prognosis | 15 | 2025 | 2100 | 0.450 |
Why?
| | Immunotherapy | 1 | 2016 | 251 | 0.420 |
Why?
| | Translocation, Genetic | 5 | 2021 | 266 | 0.410 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 475 | 0.400 |
Why?
| | Positron-Emission Tomography | 4 | 2025 | 297 | 0.400 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 853 | 0.390 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2025 | 131 | 0.380 |
Why?
| | Mutation | 6 | 2022 | 1331 | 0.380 |
Why?
| | Neoplasm, Residual | 6 | 2025 | 169 | 0.380 |
Why?
| | Neutropenia | 2 | 2023 | 113 | 0.370 |
Why?
| | Gene Expression Profiling | 9 | 2025 | 1099 | 0.370 |
Why?
| | Survival Analysis | 8 | 2024 | 656 | 0.360 |
Why?
| | Stem Cell Transplantation | 4 | 2022 | 188 | 0.360 |
Why?
| | Neoplasms | 2 | 2012 | 1313 | 0.350 |
Why?
| | Cytokine-Induced Killer Cells | 1 | 2011 | 2 | 0.350 |
Why?
| | Lymphocytes | 1 | 2012 | 146 | 0.350 |
Why?
| | Evolution, Molecular | 2 | 2021 | 98 | 0.330 |
Why?
| | Cancer Vaccines | 1 | 2011 | 78 | 0.330 |
Why?
| | Aged, 80 and over | 10 | 2025 | 3450 | 0.320 |
Why?
| | Middle Aged | 21 | 2025 | 13136 | 0.310 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2024 | 639 | 0.300 |
Why?
| | Female | 27 | 2025 | 28286 | 0.300 |
Why?
| | Cytokines | 1 | 2012 | 622 | 0.300 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 257 | 0.280 |
Why?
| | Hematologic Neoplasms | 2 | 2022 | 101 | 0.270 |
Why?
| | Neoplasm Proteins | 3 | 2020 | 328 | 0.270 |
Why?
| | Adult | 18 | 2025 | 14212 | 0.260 |
Why?
| | Male | 25 | 2025 | 26882 | 0.260 |
Why?
| | Combined Modality Therapy | 4 | 2024 | 641 | 0.260 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 195 | 0.250 |
Why?
| | Fluorodeoxyglucose F18 | 4 | 2021 | 181 | 0.220 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2025 | 63 | 0.220 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2021 | 47 | 0.220 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 75 | 0.210 |
Why?
| | Disease Progression | 6 | 2025 | 870 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1020 | 0.200 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2023 | 95 | 0.190 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 75 | 0.190 |
Why?
| | Risk Factors | 9 | 2024 | 3972 | 0.180 |
Why?
| | Paraproteinemias | 1 | 2022 | 72 | 0.180 |
Why?
| | Drug Approval | 1 | 2022 | 39 | 0.180 |
Why?
| | Immunoconjugates | 1 | 2022 | 37 | 0.180 |
Why?
| | Osteolysis | 1 | 2022 | 74 | 0.180 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2022 | 38 | 0.180 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 60 | 0.180 |
Why?
| | Treatment Outcome | 7 | 2022 | 5508 | 0.180 |
Why?
| | Patient Participation | 1 | 2022 | 65 | 0.180 |
Why?
| | Epigenomics | 1 | 2021 | 75 | 0.170 |
Why?
| | Retrospective Studies | 8 | 2025 | 6695 | 0.170 |
Why?
| | T-Lymphocytes | 4 | 2024 | 318 | 0.170 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.160 |
Why?
| | Cell Cycle | 1 | 2021 | 236 | 0.160 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 498 | 0.160 |
Why?
| | Bone Resorption | 1 | 2022 | 300 | 0.160 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.160 |
Why?
| | Bone Diseases | 1 | 2021 | 91 | 0.160 |
Why?
| | Chromosomal Instability | 1 | 2019 | 16 | 0.150 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.150 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 112 | 0.150 |
Why?
| | Antigens, CD | 1 | 2020 | 213 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2022 | 292 | 0.150 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 9 | 0.150 |
Why?
| | Spleen | 1 | 2019 | 166 | 0.140 |
Why?
| | Spinal Fractures | 1 | 2018 | 38 | 0.140 |
Why?
| | Phosphotransferases | 1 | 2018 | 17 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 1215 | 0.140 |
Why?
| | Bacteremia | 1 | 2019 | 87 | 0.140 |
Why?
| | Adipocytes | 1 | 2018 | 127 | 0.140 |
Why?
| | Gene Rearrangement | 1 | 2018 | 76 | 0.130 |
Why?
| | Recurrence | 4 | 2024 | 680 | 0.130 |
Why?
| | Hexokinase | 1 | 2017 | 16 | 0.130 |
Why?
| | Calcification, Physiologic | 1 | 2017 | 42 | 0.130 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 396 | 0.130 |
Why?
| | Cell Proliferation | 4 | 2023 | 1013 | 0.130 |
Why?
| | Pelvis | 1 | 2017 | 65 | 0.130 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 109 | 0.130 |
Why?
| | Immunoglobulin Light Chains | 1 | 2017 | 90 | 0.120 |
Why?
| | Clonal Evolution | 1 | 2016 | 57 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 180 | 0.120 |
Why?
| | Gene Expression | 1 | 2018 | 618 | 0.120 |
Why?
| | Transcriptome | 3 | 2025 | 357 | 0.110 |
Why?
| | Animals | 4 | 2024 | 13485 | 0.110 |
Why?
| | Cystatin M | 2 | 2024 | 17 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 1676 | 0.100 |
Why?
| | Disease-Free Survival | 3 | 2019 | 461 | 0.100 |
Why?
| | Survival Rate | 3 | 2020 | 944 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2017 | 493 | 0.090 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2011 | 58 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2016 | 1483 | 0.080 |
Why?
| | Mutation Rate | 2 | 2021 | 36 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2023 | 262 | 0.080 |
Why?
| | Genomics | 2 | 2023 | 266 | 0.080 |
Why?
| | Alleles | 2 | 2021 | 279 | 0.080 |
Why?
| | Tumor Burden | 2 | 2020 | 132 | 0.080 |
Why?
| | Histones | 2 | 2021 | 315 | 0.070 |
Why?
| | Vaccination | 1 | 2011 | 294 | 0.070 |
Why?
| | Transcription Factors | 2 | 2023 | 570 | 0.070 |
Why?
| | Radiopharmaceuticals | 2 | 2021 | 198 | 0.070 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 116 | 0.070 |
Why?
| | Models, Biological | 1 | 2011 | 735 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2011 | 302 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2022 | 667 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2024 | 2294 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 485 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 150 | 0.060 |
Why?
| | Biopsy | 2 | 2018 | 595 | 0.060 |
Why?
| | ROC Curve | 1 | 2025 | 250 | 0.050 |
Why?
| | Arkansas | 2 | 2021 | 2014 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 111 | 0.050 |
Why?
| | Ferritins | 1 | 2024 | 36 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 15 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 79 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 140 | 0.050 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2024 | 57 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 144 | 0.050 |
Why?
| | Mice | 2 | 2024 | 5899 | 0.050 |
Why?
| | Signal Transduction | 2 | 2021 | 1724 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| | Patients | 1 | 2022 | 51 | 0.050 |
Why?
| | Geography | 1 | 2022 | 65 | 0.050 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2022 | 32 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 89 | 0.040 |
Why?
| | Patient Selection | 1 | 2023 | 269 | 0.040 |
Why?
| | Oncogenes | 1 | 2021 | 61 | 0.040 |
Why?
| | Dexamethasone | 1 | 2024 | 434 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2022 | 110 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2023 | 295 | 0.040 |
Why?
| | Phylogeny | 1 | 2022 | 229 | 0.040 |
Why?
| | Syndecan-1 | 1 | 2021 | 73 | 0.040 |
Why?
| | RANK Ligand | 1 | 2022 | 188 | 0.040 |
Why?
| | SOXC Transcription Factors | 1 | 2021 | 13 | 0.040 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 90 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2021 | 127 | 0.040 |
Why?
| | Remission Induction | 1 | 2021 | 218 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 76 | 0.040 |
Why?
| | Chromatin | 1 | 2021 | 143 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 230 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 67 | 0.040 |
Why?
| | Pyrimidines | 1 | 2022 | 199 | 0.040 |
Why?
| | Cyclin D2 | 1 | 2020 | 21 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 19 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.040 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| | ras Proteins | 1 | 2020 | 62 | 0.040 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 31 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2020 | 59 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 56 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 121 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2020 | 76 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 146 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 231 | 0.040 |
Why?
| | Osteoclasts | 1 | 2022 | 423 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 179 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1429 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 226 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 178 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2022 | 218 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 601 | 0.040 |
Why?
| | Computational Biology | 1 | 2020 | 209 | 0.040 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 29 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 247 | 0.040 |
Why?
| | Pseudomonas Infections | 1 | 2019 | 55 | 0.040 |
Why?
| | Fractures, Compression | 1 | 2018 | 17 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 423 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 465 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 61 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 92 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 56 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2017 | 64 | 0.030 |
Why?
| | Bone and Bones | 1 | 2021 | 492 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 126 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 576 | 0.030 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 92 | 0.030 |
Why?
| | Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| | Genes, p53 | 1 | 2016 | 50 | 0.030 |
Why?
| | NF-kappa B | 1 | 2018 | 326 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 573 | 0.030 |
Why?
| | Glycolysis | 1 | 2016 | 70 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 270 | 0.030 |
Why?
| | Models, Genetic | 1 | 2016 | 173 | 0.030 |
Why?
| | Genomic Instability | 1 | 2016 | 87 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 96 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 932 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 147 | 0.030 |
Why?
| | Heart | 1 | 2017 | 352 | 0.030 |
Why?
| | Kidney Diseases | 1 | 2017 | 230 | 0.030 |
Why?
| | Algorithms | 1 | 2018 | 673 | 0.030 |
Why?
| | Echocardiography | 1 | 2017 | 408 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 2987 | 0.030 |
Why?
| | Disease Management | 1 | 2015 | 185 | 0.030 |
Why?
| | Myocardium | 1 | 2017 | 471 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2016 | 758 | 0.030 |
Why?
| | Risk Assessment | 1 | 2018 | 1349 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 1141 | 0.020 |
Why?
| | United States | 1 | 2022 | 5215 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2011 | 193 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 1508 | 0.020 |
Why?
|
|
Thanendrarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|